Recommendation of the President – Livmarli (maralixibat chloride)

On 14 May 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 60/2025 on the appraisal of drug Livmarli (maralixibat chloride) under the new drug program “Treatment of patients with Alagille syndrome (ICD-10 Q44.7)”